ARTV
Artiva Biotherapeutics, Inc.
A clinical-stage biotechnology company in San Diego making off-the-shelf natural killer (NK) cell therapies, its lead candidate AlloNK designed to help antibodies destroy B-cells that drive autoimmune diseases like rheumatoid arthritis and lupus. Founded in 2019 as a spin-out of South Korea's GC Cell, it can produce thousands of doses from a single umbilical cord blood donor—a ready-made therapy that doesn't wait for a patient's own cells.
CUSIP: 04317A107HealthcareUS1 holder
Total Value
$25.26M
Total Shares
2.60M
Net Share Change
+2.60M
Activity
1 buying
Investor
Value
Shares
Weight
Change
